Clinical Trials Directory

Trials / Completed

CompletedNCT01702974

Immune Reconstitution in HIV Disease (IREHIV)

Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
279 (actual)
Sponsor
Karolinska Institutet · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The aim with this study is to provide immunotherapy with vitamin D and phenylbutyrate to treatment-naive HIV infected patients to induce important antimicrobial defence mechanisms and decreased inflammation.

Conditions

Interventions

TypeNameDescription
DRUGvitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
DRUGPlacebo tabletsPlacebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.

Timeline

Start date
2012-09-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2012-10-10
Last updated
2016-02-05

Locations

1 site across 1 country: Ethiopia

Source: ClinicalTrials.gov record NCT01702974. Inclusion in this directory is not an endorsement.

Immune Reconstitution in HIV Disease (IREHIV) (NCT01702974) · Clinical Trials Directory